中
  • HOME

  • Company

    • GenFleet Overview
    • Vision & Mission
    • Management Team
    • Advisory Board
    • Company History
    • CSR Philosophy
  • Science

    • Our Pipeline
    • Selected Targets
    • R&D Platform
  • Media

    • Press Release
    • Media Coverage
  • Investors

    • Institutional Investors
    • IR Announcements
  • Careers

    • Overview
    • Culture
    • Highlights
    • Benefits
    • Join Us
  • Contact

jinfangLOGOzuhejihekouhao-05.png

HOME

Company

  • GenFleet Overview
  • Vision & Mission
  • Management Team
  • Advisory Board
  • Company History
  • CSR Philosophy

Science

  • Our Pipeline
  • Selected Targets
  • R&D Platform

Media

  • Press Release
  • Media Coverage

Investors

  • Institutional Investors
  • IR Announcements

Careers

  • Overview
  • Culture
  • Highlights
  • Benefits
  • Join Us

Contact

中
Home
Media
Press Release
  • GenFleet Therapeutics and BioLineRx Announces Collaboration Agreement to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC)

    GenFleet will fully design and execute a randomized Phase 2b clinical trial. GenFleet will be eligible to receive tiered percentage royalties on future Motixafortide sales, if approved.

    Jun 29, 2022
  • Phase I Data for GFH925 Monotherapy Presented at 2022 ASCO

    The clinical data of GFH925 dose escalation part of the phase I trial (NCT05005234), currently conducted by Innovent, will be released as a poster at ASCO held from June 3-7th.

    Jun 05, 2022
  • GenFleet and SELLAS Announce Global License Agreement

    We are pleased that GFH009, one of the leading assets in our first-in-class portfolio, will now be developed and commercialized on a worldwide basis

    Apr 01, 2022
  • GenFleet Appoints Dr. Jingrong Li as Chief Technology Officer

    Bringing in over two decades of experiences in the pharmaceutical industry, Dr. Li was involved in numerous programs of approved drugs and diagnostics. His expertise ranges from process development, quality control validation, scale-up manufacturing to other core technologies related with the upstream & downstream sectors of the industry and led various teams to develop preclinical and clinical batches of different monoclonal antibodies, therapeutic vaccines and recombinant protein products.

    Jan 04, 2022
  • GenFleet Therapeutics Raises $75 Million in Series C Financing Led by Huagai Capital, to Advance Innovative Pipeline Highlighting Cutting-edge Therapies

    This round of financing is led by Huagai Capital, with participation by new investors including Suxin Venture Capital, Cherami Investment Group, ABC International, DYEE Capital, Qiaojing Eastern Investment, Baidu Venture, and Wenzhou Capital. Existing investors including CDH Venture and Growth Capital, Lake Bleu Capital, HM Capita, Panlin Capital, Shanjin Asset also participated. Start Point Advisors act as the sole financial advisor.

    Dec 31, 2021
  • GenFleet Announces First Patient Dosed in Phase Ib/II Trial of TGF-β R1 Inhibitor in Combination with PD-1 Inhibitor in Global Multi-center Research

    This multi-center trial the first POC (proof of concept) study designed by GenFleet and it's also the company's third program involving global research sites. GFH018 demonstrated excellent safety profile in phase I trial. Preclinical data also suggested antitumor effects of low-dose GFH018 in combination with PD-1 inhibitors.

    Oct 21, 2021
  • GenFleet and Innovent Starts First-in-human Phase I/II Trial of KRAS G12C Inhibitor

    Designed to enroll over 100 patients with late stage NSCLC and gastrointestinal cancer, the study will evaluate the safety/tolerability/efficacy and characterize the pharmacokinetics profile of GFH925

    Sep 30, 2021
  • GenFleet and Innovent Announce Exclusive Global License Agreement for GFH925 (KRAS G12C Inhibitor)

    GenFleet Therapeutics and Innovent jointly announced that they have entered into an exclusive license agreement for the development and commercialization of GenFleet's lead KRAS G12C candidate, GFH925 in China with additional option-in rights for global development and commercialization.

    Sep 02, 2021
  • 1
  • 2
  • 3
Next
jinfangLOGOzuhejihekouhao-08.png
Company
Science
Media
Investors
Careers
Contact
GenFleet Therapeutics (Shanghai)

1206 Zhangjiang Road, Building A, Shanghai

021-6882 1388

201203

GenFleet Therapeutics (Zhejiang)

1 Yunhai Road, Building 3 (Southern Division), Level 4, Shaoxing City, Zhejiang Province

0575-8258 6890

312000

Offical Wechat
qrcode_for_gh_ae7817a32e15_258.jpg
GenFleeter Wechat
jinfangren-121.jpg
Copyright © 2021 GenFleet Therapeutics (Shanghai) Inc  |  沪ICP备18009875号